Cover Image

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, ide...

Full description

Saved in:
Bibliographic Details
Main Authors: Bednarova, Sandra (Author) , Lindenberg, Maria L. (Author) , Vinsensia, Maria (Author) , Zuiani, Chiara (Author) , Choyke, Peter L. (Author) , Turkbey, Baris (Author)
Format: Article (Journal)
Language:English
Published: June 2017
In: Translational andrology and urology
Year: 2017, Volume: 6, Issue: 3, Pages: 413-423
ISSN:2223-4691
DOI:10.21037/tau.2017.03.53
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/tau.2017.03.53
Verlag, kostenfrei, Volltext: http://tau.amegroups.com/article/view/14056
Get full text
Author Notes:Sandra Bednarova, Maria L. Lindenberg, Maria Vinsensia, Chiara Zuiani, Peter L. Choyke, Baris Turkbey
Description
Summary:Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa. However, some PET agents have shown remarkable promise in staging high-risk PCa (defined as any combination of a clinical T3, a PSA score >20 ng/mL, or a Gleason score of 8-10), as well as biochemical relapse after definitive therapy and metastatic PCa. PET agents can be divided into those that interrogate tumor metabolism ( 18 F-FDG, 11 C-Choline, 18 F-Choline, 11 C-Acetate, 18F-FACBC), hormone receptors (18F-FDHT), and other targets such as prostate specific membrane antigen (PSMA) ( 68 Ga-PSMA, 18 F-DCFBC, 18 F-DCFPyl) or gastric releasing peptide ( 18 F-GRP or 18 F-Bombesin). In this review, we compare the available PCa targeted PET tracers utilized in staging of high risk tumors.
Item Description:Gesehen am 02.11.2018
Physical Description:Online Resource
ISSN:2223-4691
DOI:10.21037/tau.2017.03.53

Similar Items